• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Beigene

Quote
anonymous said:
Incorrect. But, keep spinning not getting the job.
Click to expand...

Really? So what day was your strike price for your RSU’s? We can do the math to see how many you received. Based on when I got my offer letter I would have received around 600 RSU’s based on the $125k of value...so I’d be sitting on a whopping 150 shares vested...so about $33,000 pre tax. Prove me wrong...
 




anonymous said:
Really? So what day was your strike price for your RSU’s? We can do the math to see how many you received. Based on when I got my offer letter I would have received around 600 RSU’s based on the $125k of value...so I’d be sitting on a whopping 150 shares vested...so about $33,000 pre tax. Prove me wrong...
Click to expand...


All true.
 












anonymous said:
Really? So what day was your strike price for your RSU’s? We can do the math to see how many you received. Based on when I got my offer letter I would have received around 600 RSU’s based on the $125k of value...so I’d be sitting on a whopping 150 shares vested...so about $33,000 pre tax. Prove me wrong...
Click to expand...

They can’t. Your numbers are accurate. It’s peanuts at this point.
 




anonymous said:
They can’t. Your numbers are accurate. It’s peanuts at this point.
Click to expand...

The numbers are accurate, minus the additional equity that was given later. Only 1/4th of the original RSUs did recently vest and the value of those and the others did absolutely drop significantly. My point was they have potential to be worth a decent amount in the future. Equity is a risk regardless. Ask some of the reps from Clovis, Karyopharm, Puma, or any startup how their equity has worked out? Sometimes it works out and sometimes it doesn’t.

I also didn’t come here to get rich off of the equity. To me, it’s part of the overall compensation package. If you do actually work here, we’re on the same team, so I wish you well.
 




anonymous said:
The numbers are accurate, minus the additional equity that was given later. Only 1/4th of the original RSUs did recently vest and the value of those and the others did absolutely drop significantly. My point was they have potential to be worth a decent amount in the future. Equity is a risk regardless. Ask some of the reps from Clovis, Karyopharm, Puma, or any startup how their equity has worked out? Sometimes it works out and sometimes it doesn’t.

I also didn’t come here to get rich off of the equity. To me, it’s part of the overall compensation package. If you do actually work here, we’re on the same team, so I wish you well.
Click to expand...

Sure some work out...Genentech, Onyx, MGI, PCYC, and some do not, like those you mentioned...however we have very little skin in the game here so having any meaningful upside we’d need the share price to more than quadruple while getting a lot more RSU’s each year...fairly certain that’s not happening.

So if you didn’t come here to get rich off the equity why did you? The late to market undifferentiated me too products, mediocre base/IC, or the lackluster commercial and sales “leadership”? What was your driving factor?
 




anonymous said:
Sure some work out...Genentech, Onyx, MGI, PCYC, and some do not, like those you mentioned...however we have very little skin in the game here so having any meaningful upside we’d need the share price to more than quadruple while getting a lot more RSU’s each year...fairly certain that’s not happening.

So if you didn’t come here to get rich off the equity why did you? The late to market undifferentiated me too products, mediocre base/IC, or the lackluster commercial and sales “leadership”? What was your driving factor?
Click to expand...

When the stock was 300+ our accounts were in the range of 250-300, which is not bad after a year. The above post failed to mention Celgene which was the home to many of the reps here so many can work without having to "get rich", they already should be. The company bonus has been better than average considering the year. The drug, and the drugs behind it are all me too under the best assumptions, with very little trial exposure in the US. I know many are looking to leave for different reasons. At this company the US market does not make a difference and the drugs will probably not either so you have to be hopeful that things work out in China. Lastly managment has been fine, what do you expect or need from them?
 




anonymous said:
When the stock was 300+ our accounts were in the range of 250-300, which is not bad after a year. The above post failed to mention Celgene which was the home to many of the reps here so many can work without having to "get rich", they already should be. The company bonus has been better than average considering the year. The drug, and the drugs behind it are all me too under the best assumptions, with very little trial exposure in the US. I know many are looking to leave for different reasons. At this company the US market does not make a difference and the drugs will probably not either so you have to be hopeful that things work out in China. Lastly managment has been fine, what do you expect or need from them?
Click to expand...
Many who left Celgene were desperate or upset for being passed over during BMS acquisition. Upon resignation they were forced to sell CELG shares that were underwater or of minimal value because of strike prices leaving them not so rich as described.
 




anonymous said:
Many who left Celgene were desperate or upset for being passed over during BMS acquisition. Upon resignation they were forced to sell CELG shares that were underwater or of minimal value because of strike prices leaving them not so rich as described.
Click to expand...


I had over 10k shares that i made about 100 per share on....... do the math.....
 
















anonymous said:
I was there for 13 years yet I made more in stock than through salary/bonus. The poster from ealier must not know how to read a stock chart.
Click to expand...
I was there for 15 years and did well for sure but gotta know when to fold ‘em. Besides options contracts expired at 10 years if not exercised. Those were the days to make money not when Beigene was initially hiring and exercisable Celgene options had very high strike prices from those good old days when they were granted.
 
















I know I was not wanting to sell the 8th to market checkpoint inhibitor. I am very excited though to sell the 4th to market parp inhibitor.

Sincerely
Wuhan used car salesman
 




China says you go sell more bad data drug or we no give more than 8 grand bonus. You tell American Dr our data good from China. you also no pay attention to crazy stock movement when you can no sell drug.
 








Top Bottom
Back
Quote